Corticosteroids for Eosinophilic Esophagitis in Children: A Meta-analysis.
| Autor: | Munoz-Osores E; Division of Pediatrics., Maldonado-Campos I; Division of Pediatrics., Olivares-Labbe MT; UC Library System (SIBUC), Pontificia Universidad Católica de Chile, Santiago, Chile., Villarroel L; Department of Public Health, Faculty of Medicine, and., Gana JC; Division of Pediatrics, jcgana@gmail.com.; Department of Gastroenterology and Nutrition, Escuela de Medicina, and. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Pediatrics [Pediatrics] 2020 Nov; Vol. 146 (5). |
| DOI: | 10.1542/peds.2020-0874 |
| Abstrakt: | Context: Treatment of eosinophilic esophagitis (EoE) is focused on dietary, pharmacologic, and endoscopic therapy options. Within the pharmacologic alternatives, topical corticosteroids are the most used, and a large number of studies evaluating their effectiveness have been published, requiring a new summary of evidence. Objective: To evaluate the histologic and clinical effectiveness of the use of corticosteroids in pediatric patients with a diagnosis of EoE. Data Sources: Cochrane Central Register of Controlled Trials, Medline, Embase, Science Citation Index Expanded, Conference Proceedings Citation Index-Science, Latin American and Caribbean Health Sciences Literature, and ClinicalTrials.gov (June 2019). Study Selection: We selected randomized controlled trials assessing corticosteroids versus a placebo or dietary treatment of EoE in children. Data Extraction: Methodologic quality of evidence was evaluated by using the Cochrane Collaboration's risk of bias tool and the Grading of Recommendations Assessment, Development, and Evaluation system. The primary outcomes were clinical and histologic improvement. Results: A total of 1655 studies were identified. Five studies were included (206 patients). Histologic response was 49.25% in the corticosteroids group and 4.16% in the placebo group (risk ratio 11.05 [confidence interval 3.8-32.15]; P < .0001). Symptomatic response was 33.6% in the corticosteroids group and 21.8% in the control group (risk ratio 1.62 [confidence interval 0.94-2.79]; P = .08). There were no major adverse effects. Limitations: Heterogeneity of the diagnosis of EoE. Conclusions: Our review revealed favorable results of corticosteroids versus placebo, mainly in histologic response. More studies are needed, by using validated clinical scores, to obtain more reliable results. Competing Interests: POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose. (Copyright © 2020 by the American Academy of Pediatrics.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|